
Quinn Emanuel Urquhart & Sullivan announced that Kevin Hardy has joined the firm as a partner. Hardy – previously a partner and co-chair of patent litigation at Williams & Connolly, will be resident in Quinn Emanuel’s Washington, DC office.
“We are delighted to welcome Kevin to the firm. He has been lead counsel in a number of groundbreaking intellectual property disputes, including patent and royalty disputes, and has played key roles in antitrust cases that involve the intersection of intellectual property and antitrust law,” said firm founder John B. Quinn. “Our intellectual property practice remains one of our most important practice areas, and we’re gratified to add a talent of Kevin’s caliber.”
As part of his patent litigation practice, Hardy also has represented clients in inter partes review and covered business method patent review proceedings before the Patent Office. He was recently recognized by Managing IP as an IP Star and has repeatedly been recognized in IAM 1000 – The World’s Leading Patent Practitioners, which cited his “ability to identify, capture and clearly articulate the relevant legal issues in litigation and licensing negotiations” and his “adroitness at the confluence of IP and antitrust law.”
In recent years, Hardy’s practice has encompassed matters involving the licensing and enforcement of standard essential patents in wireless technology as well as representation of pharmaceutical clients in so-called “pay-for-delay” and related matters. He has litigated patent cases in US district courts across the country.
“Quinn Emanuel’s intellectual property practice is arguably the best in the world. Its reputation as the leading firm in IP and patent disputes made joining this team too appealing to resist,” Hardy said.
Full Content:
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas